Page last updated: 2024-09-04

irofulven and Abnormalities, Autosome

irofulven has been researched along with Abnormalities, Autosome in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Reed, E; Senft, J; Wang, W; Wang, Y; Wiltshire, T	1

Other Studies

1 other study(ies) available for irofulven and Abnormalities, Autosome

Article	Year
Irofulven induces replication-dependent CHK2 activation related to p53 status. Biochemical pharmacology, 2007, Feb-15, Volume: 73, Issue:4 Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Checkpoint Kinase 2; Chromosome Aberrations; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; G1 Phase; G2 Phase; HCT116 Cells; Histones; Humans; Phosphorylation; Protein Serine-Threonine Kinases; S Phase; Sesquiterpenes; Tumor Suppressor Protein p53	2007

Article

Year

Irofulven induces replication-dependent CHK2 activation related to p53 status.

Biochemical pharmacology, 2007, Feb-15, Volume: 73, Issue:4

Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Checkpoint Kinase 2; Chromosome Aberrations; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; G1 Phase; G2 Phase; HCT116 Cells; Histones; Humans; Phosphorylation; Protein Serine-Threonine Kinases; S Phase; Sesquiterpenes; Tumor Suppressor Protein p53

2007